Pediatric Allergy Management: Navigating Diagnostic Hurdles and Treatment

The management of seasonal allergic rhinitis in children represents a significant clinical and economic challenge for pediatric healthcare systems. As seasonal shifts become more pronounced, the window for allergic triggers has expanded, leading to a higher volume of pediatric visits that often overlap with the tail end of the viral respiratory season. The primary difficulty for clinicians lies in the diagnostic differentiation between allergic rhinitis and common viral infections, such as the common cold or mild influenza. While both present with rhinorrhea and congestion, the underlying pathophysiology and subsequent treatment pathways are vastly different. Misdiagnosis not only delays appropriate symptom relief but also contributes to the overuse of antibiotics in pediatric populations—a persistent concern in global health.

From a clinical perspective, identifying the "allergic salute" (a transverse crease across the nose from frequent upward rubbing) and "allergic shiners" (dark circles under the eyes caused by venous congestion) provides critical clues that point toward an atopic origin rather than an infectious one. Unlike viral infections, which typically resolve within seven to ten days and may involve low-grade fever or muscle aches, seasonal allergies can persist for weeks or months, fluctuating with pollen counts. The absence of fever and the presence of intense ocular or nasal pruritus (itching) are hallmark indicators that favor a diagnosis of allergic rhinitis.

The treatment landscape for pediatric allergies is currently characterized by a shift toward more potent, non-sedating options. Intranasal corticosteroids (INCS) have solidified their position as the first-line therapy for children with persistent or moderate-to-severe symptoms. These medications are highly effective at reducing the inflammatory response in the nasal mucosa, though they require consistent daily use to achieve maximum efficacy. For many families, the transition of several high-potency INCS from prescription-only to over-the-counter (OTC) status has improved accessibility but has also increased the need for clinician-led education on proper administration techniques to avoid local side effects like epistaxis.